



UPDATE ON STATUS OF DOJ INVESTIGATION

4 November 2016, Adelaide Australia: Previously on 28 Jun 2016, Mayne Pharma Group Limited disclosed that it was one of several generic companies to receive a subpoena from the Antitrust Division of the US Department of Justice (DOJ) seeking information relating to the marketing, pricing and sales of select generic products. The investigation relating to Mayne Pharma is focused on doxycycline hyclate delayed-release tablets (generic) and potassium chloride powders.

Contrary to an inaccurate statement made in the US press overnight, Mayne Pharma has previously stated that it is cooperating with the DOJ in its investigation and continues to do so. Mayne Pharma continues to believe these investigations will not have a material impact on its future earnings. However, no assurance can be given as to the timing or outcome of the investigation.

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

